BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palamaris K, Felekouras E, Sakellariou S. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers (Basel) 2021;13:5532. [PMID: 34771695 DOI: 10.3390/cancers13215532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kung HC, Yu J. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm (2020) 2023;4:e216. [PMID: 36814688 DOI: 10.1002/mco2.216] [Reference Citation Analysis]
2 Lee W, Song G, Bae H. Glucotropaeolin Promotes Apoptosis by Calcium Dysregulation and Attenuates Cell Migration with FOXM1 Suppression in Pancreatic Cancer Cells. Antioxidants (Basel) 2023;12. [PMID: 36829815 DOI: 10.3390/antiox12020257] [Reference Citation Analysis]
3 Khales SA, Mozaffari-Jovin S, Geerts D, Abbaszadegan MR. TWIST1 activates cancer stem cell marker genes to promote epithelial-mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma. BMC Cancer 2022;22:1272. [PMID: 36474162 DOI: 10.1186/s12885-022-10252-9] [Reference Citation Analysis]
4 Kim EY, Lee SU, Kim YH. 1,2,3,4,6-Penta-O-galloyl-β-D-glucose Inhibits CD44v3, a cancer stem cell marker, by regulating its transcription factor, in human pancreatic cancer cell line. Anim Cells Syst (Seoul) 2022;26:328-37. [PMID: 36605595 DOI: 10.1080/19768354.2022.2152864] [Reference Citation Analysis]
5 Greco L, Rubbino F, Laghi L. Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men. Cancers (Basel) 2022;14. [PMID: 36497278 DOI: 10.3390/cancers14235797] [Reference Citation Analysis]
6 Wright CA, Gordon ER, Cooper SJ. HDAC1 overexpression alters GTPase activity impacting chemoresistance in pancreatic cancer.. [DOI: 10.1101/2022.09.06.506214] [Reference Citation Analysis]
7 Puik JR, Swijnenburg R, Kazemier G, Giovannetti E. Novel Strategies to Address Critical Challenges in Pancreatic Cancer. Cancers 2022;14:4115. [DOI: 10.3390/cancers14174115] [Reference Citation Analysis]
8 Wu L, Ge Y, Yuan Y, Li H, Sun H, Xu C, Wang Y, Zhao T, Wang X, Liu J, Gao S, Chang A, Hao J, Huang C. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Cancer Lett 2022;:215864. [PMID: 35981571 DOI: 10.1016/j.canlet.2022.215864] [Reference Citation Analysis]
9 Lee W, Song G, Bae H. Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells. Mar Drugs 2022;20:473. [PMID: 35892941 DOI: 10.3390/md20080473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 2022;11:2155. [PMID: 35883598 DOI: 10.3390/cells11142155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Khaled J, Kopsida M, Lennernäs H, Heindryckx F. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells 2022;11:632. [DOI: 10.3390/cells11040632] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]